Эффективность anti-VEGF-препарата «Ранибизумаб» при лечении ретинопатии недоношенных

    1. Castellanos M.A., Schwartz S., Garcia-Aguirre G., QuirozMercado H. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity// Br. J. Ophthalmol. – 2013. – Vol. 97. – P. 816-819.

    2. Chan J.J., Lam C.P., Kwok M.K. et al. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy // J. Scientific Reports. – 2016. – Vol. 6. – P.1-6.

    3. Chen S.N., Lian I., Hwang Y.C. et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab // Retina. – 2015. – Vol. 35, № 4. – P. 667-674.

    4. Erol M.K., Coban D.T., Sari E.S. et al. Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity // Arq. Bras. Oftalmol. – 2015. – Vol. 78. – P. 340-343.

    5. Goodyear M.D.E., Krleza-Jeric K, Lemmens T. The Declaration of Helsinki // British Medical Journal. – 2007. – Vol. 335, № 7621. – P. 624-625.

    6. Hoerster R., Muether P., Dahlke C. et al. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity // Acta Ophthalmol. – 2013. – Vol. 91. – P. 74-75.

    7. Yau G.S., Lee J.W., Tam V.T. et al. Insidence and risk factors for retinopathy of prematurity in multiple gestations: a Chinese population study // Medicine (Baltimore). – 2015. – Vol. 94, № 18. – P. 1-6.

    8. Wong R.K., Hubschman S., Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment // Retina. – 2015. – Vol. 35. – P. 675-680.